Hansa Medical initiates follow up study of patients treated with lead candidate imlifidase (IdeS) prior to kidney transplantation
Hansa Medical today announced that a long-term observational prospective follow up study (ClinicalTrials.gov Identifier: NCT03611621) has been initiated with Hansa Medical as sponsor. The primary objective of the study is evaluation of graft survival in patients who have undergone kidney transplantation after treatment with imlifidase. The study aims to encompass all patients from the Phase II studies with imlifidase in sensitized kidney transplantation patients.Imlifidase (INN), also known as IdeS, is an enzyme that depletes IgG antibodies fast and effectively. Hansa Medical is developing